MedTrace Logo

A Cohort Study Comparing IFX to CS for Moderate to Severe UC

NCT04879966 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 342

Last updated 2022-11-25

No results posted yet for this study

Summary

The first-line treatment strategy of moderate to severe UC was a important question at issue. The biological agents had potentiality to alter the disease course of UC. The AGA clinical guidelines had conditional recommend that IFX and other biological agene migtht be first-line therapy for high-risk UC patints but only had low grade evidence.We launched this multicenter prospective cohort trial to compare the efficacy and safety of infliximab (IFX) and corticosteroids(CS) when they was used as first-line therapy in UC patients.

Conditions

  • Moderate to Severe Ulcerative Colitis

Interventions

DRUG

Infliximab

Infliximab was used as induction therapy in UC patients, the maintenance treatment was decided by the researcher

DRUG

Corticosteroid

Corticosteroids was used as induction therapy in UC patients, the maintenance treatment was decided by the researcher

Sponsors & Collaborators

  • Sixth Affiliated Hospital, Sun Yat-sen University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-17
Primary Completion
2022-12-31
Completion
2023-12-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04879966 on ClinicalTrials.gov